Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dopamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 7/20 | 0.59 |
| ▸ | MAPT | P10636 | 5/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.59 |
| ▸ | DRD2 | P14416 | 2/20 | 0.59 |
| ▸ | DRD1 | P21728 | 2/20 | 0.59 |
| ▸ | DRD4 | P21917 | 2/20 | 0.59 |
| ▸ | DRD5 | P21918 | 2/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.59 |
| ▸ | DRD3 | P35462 | 2/20 | 0.59 |
| ▸ | RECQL | P46063 | 2/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.59 |
| ▸ | THPO | P40225 | 2/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dopamine SCHEMBL29516726 | 1.00 | ALOX15 (0.59) | ALOX15MAPTKDM4EMAPK1ALDH1A1 | |
| Dopamine SCHEMBL29516921 | 0.98 | MAPT (0.60) | ALOX15MAPTKDM4EMAPK1ALDH1A1 | |
| Dopamine SCHEMBL413926 | 0.84 | CA1 (0.50) | ALOX15MAPTKDM4EMAPK1ALDH1A1 | |
| Dopamine SCHEMBL50430 | 0.84 | CA1 (0.50) | ALOX15MAPTKDM4EMAPK1ALDH1A1 | |
| Dopamine SCHEMBL29810038 | 0.84 | CA1 (0.50) | ALOX15MAPTKDM4EMAPK1ALDH1A1 | |
| Dopamine SCHEMBL29538557 | 0.84 | ALOX15 (0.59) | ALOX15MAPTKDM4EMAPK1ALDH1A1 | |
| Dopamine SCHEMBL49885 | 0.84 | ALOX15 (0.59) | ALOX15MAPTKDM4EMAPK1ALDH1A1 | |
| Dopamine SCHEMBL29435413 | 0.82 | ALOX15 (0.73) | ALOX15MAPTKDM4EMAPK1ALDH1A1 | |
| Dopamine SCHEMBL50427 | 0.82 | ALOX15 (0.73) | ALOX15MAPTKDM4EMAPK1ALDH1A1 | |
| Dopamine SCHEMBL29599861 | 0.80 | MAPT (0.74) | ALOX15MAPTKDM4EMAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2353 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112782328-B | Method for detecting catecholamine and metabolites thereof in urine, kit and application of kit | 深圳华大医学检验实验室 | 2024-07-09 | — | — | CN | claimed |
| US-20230416361-A1 | ENGINEERED CD200R ANTIBODIES AND USES THEREOF | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2023-12-28 | — | — | US | claimed |
| US-20230381168-A1 | ADJUNCTIVE THERAPY FOR DEPRESSION | ANEUROTECH BV (BE) | 2023-11-30 | — | — | US | claimed |
| CN-116964198-A | System and method for producing or identifying non-human animals having a predetermined phenotype or genotype | 标准诊断公司 | 2023-10-27 | — | — | CN | claimed |
| CN-116908325-A | Sample pretreatment liquid, method and kit capable of simultaneously detecting 12 catecholamines, metabolites and creatinine in human urine | 昆明医科大学第一附属医院 | 2023-10-20 | — | — | CN | claimed |
| WO-2023196866-A1 | ENGINEERED CD200R ANTIBODIES AND USES THEREOF | MIROBIO LIMITED (GB) | 2023-10-12 | — | — | WO | claimed |
| US-20230317205-A1 | SYSTEMS AND METHODS FOR PRODUCING OR IDENTIFYING NON-HUMAN ANIMALS WITH A PREDETERMINED PHENOTYPE OR GENOTYPE | Etalon | 2023-10-05 | — | — | US | claimed |
| WO-2023183618-A1 | PSYCHEDELIC COMPOSITIONS AND METHODS FOR FORMING THE SAME | OJAI ENERGETICS PBC (US) | 2023-09-28 | — | — | WO | claimed |
| EP-4204557-A2 | SYSTEMS AND METHODS FOR PRODUCING OR IDENTIFYING NON-HUMAN ANIMALS WITH A PREDETERMINED PHENOTYPE OR GENOTYPE | Etalon Diagnostics (US) | 2023-07-05 | — | — | EP | claimed |
| CN-115932118-A | Method for improving catecholamine mass spectrum quantitative detection sensitivity by using vitamin C | 丛宇婷 | 2023-04-07 | — | — | CN | claimed |
| EP-0912552-A1 | 2,4-DIAMINOPYRIMIDINE DERIVATES AS DOPAMINE D4 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-05-06 | — | — | EP | claimed |
| EP-0912533-A1 | ALKYLAMINOBENZOTHIAZOLE AND -BENZOXAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-05-06 | — | — | EP | claimed |
| US-5885994-A | ANTIPSYCHOTIC DRUGS; SCHIZOPHRENIA | WARNER-LAMBERT COMPANY (US) | 1999-03-23 | — | — | US | claimed |
| WO-1998007710-A1 | DISUBSTITUTED MORPHOLINE, OXAZEPINE OR THIAZEPINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS DOPAMINE D4 RECEPTOR ANTAGONISTS | NEUROSEARCH A/S (DK) | 1998-02-26 | — | — | WO | claimed |
| WO-1997043279-A1 | 2,4-DIAMINOPYRIMIDINE DERIVATES AS DOPAMINE D4 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-11-20 | — | — | WO | claimed |
| WO-1997043271-A1 | ALKYLAMINOBENZOTHIAZOLE AND -BENZOXAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-11-20 | — | — | WO | claimed |
| US-5686255-A | DETERMINING AMOUNT OF MODIFIED DOPAMINE D4 RECEPTOR HAVING ADENOSYLATED METHIONINE | DETH RICHARD C (US) | 1997-11-11 | — | — | US | claimed |
| EP-0804569-A2 | EXPRESSION OF HUMAN D 4? DOPAMINE RECEPTORS IN STABLE CELL LINES | Allelix Biopharmaceuticals Inc. (CA) | 1997-11-05 | — | — | EP | claimed |
| WO-1996037780-A1 | COMPOSITIONS AND METHODS FOR DETECTING SCHIZOPHRENIA | DETH RICHARD C (US) | 1996-11-28 | — | — | WO | claimed |
| WO-1995009237-A2 | EXPRESSION OF HUMAN D4 DOPAMINE RECEPTORS IN STABLE CELL LINES | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 1995-04-06 | — | — | WO | claimed |